DigestRedComo funciona
Red
/
Empresas
Bi
No verificado

Biocytogen

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaIndustriaSalud

7 Comunicados de prensa

Ver todos los comunicados de prensa
28/02/2026
Industria
Salud
Sanidad
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034
Fuente
Biocytogen
Editor
Business Wire
1.00
0
09/01/2026
Mercado laboral
Industria
Oncología
Salud
Ciencia
Farmacéutica
Biotecnología
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)
Fuente
Biocytogen
Editor
Business Wire
1.00
0
17/06/2025
Biocytogen Responds to Harbour BioMed’s Patent Claims: RenNano® is an Independently Developed Platform with Distinct Innovation and Full Legal Standing
Fuente
Biocytogen
Editor
Business Wire
1.00
0
09/01/2025
Mercado laboral
Industria
Ciencia
Material médico sanitario
Biotecnología
Medicina - Varios
Farmacéutica
Salud
Oncología
Biocytogen Announces Licensing of Fully Human Antibodies with SOTIO to Develop Novel ADC SOT109 for Colorectal Cancer Treatment
Fuente
Biocytogen
Editor
Business Wire
1.00
0
07/01/2025
Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors
Fuente
Biocytogen
Editor
Business Wire
1.00
0
07/01/2025
Mercado laboral
Industria
Oncología
Salud
Ciencia
Farmacéutica
Biotecnología
Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors
Fuente
Biocytogen
Editor
Business Wire
1.00
0
16/07/2024
Oncología
Salud
Ciencia
Farmacéutica
Biotecnología
Mercado laboral
Industria
SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline
Fuente
Biocytogen
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0